Filing Analysis
MetaVia Inc. filed an 8-K to announce its second quarter 2026 financial results and provide a corporate update via press release. The company also updated its investor relations presentation on its website.
📋 Key Facts
- Reported financial results for the second quarter ended June 30, 2026.
- Issued a corporate update alongside the earnings release.
- Updated its corporate presentation available on the company's IR website.
MetaVia Inc. provided a clinical trial update regarding its Phase 1 study of DA-1726 for obesity treatment. All active patients have completed dose titration and are now receiving maximum target doses.
📋 Key Facts
- Phase 1 Trial (Part 3) evaluating DA-1726 for obesity treatment has reached the highest target dose stage.
- Patients in both study cohorts are now receiving doses of 48 mg and 64 mg.
- Topline data readout from the Phase 1 Trial is expected in Q4 2026.
MetaVia Inc. has filed a prospectus supplement to facilitate the sale of up to $4,000,000 in common stock through an existing At The Market (ATM) offering agreement with Ladenburg Thalmann & Co. Inc.
🚩 Red Flags
- Potential dilution for existing shareholders due to the issuance of new common stock.
- The use of an ATM offering can lead to continuous downward pressure on the stock price as shares are sold into the market.
📋 Key Facts
- The company is utilizing an 'At The Market' (ATM) offering agreement originally entered into on November 6, 2025.
- Ladenburg Thalmann & Co. Inc. is acting as the sales agent/principal.
- The prospectus supplement filed on July 2, 2026, covers the offer and sale of up to $4,000,000 in common stock.
- Honigman LLP has provided a legal opinion regarding the validity of the shares to be issued.
At its 2026 Annual Meeting on June 8, 2026, MetaVia Inc. stockholders approved a reverse stock split in a range of 1-for-5 to 1-for-22. The filing also confirms the election of two directors, the ratification of BDO USA, P.C. as auditors, and an increase of 200,000 shares to the 2022 Equity Incentive Plan.
🚩 Red Flags
- Approval of a reverse stock split is a major red flag for micro-cap companies, typically indicating a struggle to maintain minimum bid price requirements for Nasdaq listing.
- Multiple 8-K items (5.02, 5.07, 9.01) reported in a single filing.
- The reverse split ratio is wide (1-for-5 to 1-for-22), providing the board significant discretion to aggressively reduce share count.
📋 Key Facts
- Stockholders approved a reverse stock split with a ratio between 1-for-5 and 1-for-22, to be determined by the Board of Directors.
- The 2022 Equity Incentive Plan was amended to increase the pool of issuable common stock by 200,000 shares.
- BDO USA, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- D. Gordon Strickland and James P. Tursi, M.D. were elected as Class I directors for three-year terms.
- A quorum was established with 2,866,545 shares present and entitled to vote.
MetaVia Inc. announced the presentation of late-breaking clinical and preclinical data for its obesity and metabolic disease portfolio at the 2026 American Diabetes Association (ADA) Scientific Sessions. The data focuses on the Phase 1 results for DA-1726 and preclinical combination studies for vanoglipel.
📋 Key Facts
- DA-1726 (GLP1R/GCGR dual agonist) Phase 1 results showed a 9.1% reduction in body weight at Day 54 (p<0.05 vs placebo).
- DA-1726 demonstrated a reduction in waist circumference of 9.8 cm at Day 54.
- Vanoglipel (GPR119 agonist) in combination with resmetirom showed a 23.6% weight reduction in MASH mouse models (p<0.05).
- Vanoglipel in combination with metformin showed a 16.3% weight reduction versus control in hyperglycemic mouse models (p<0.05).
- DA-1726 was reported as generally well tolerated with mild-to-moderate gastrointestinal adverse events.
MetaVia Inc. announced the presentation of new Phase 1 data for its drug candidate DA-1726 (a dual GLP1R and GCGR agonist) at the European Association for the Study of the Liver Congress 2026 (EASL 2026) in Barcelona, Spain.
📋 Key Facts
- The announcement was made via a press release dated May 27, 2026.
- The data pertains to Phase 1 clinical trials of DA-1726.
- DA-1726 is a dual oxyntomodulin (OXM) analog agonist targeting GLP1R and GCGR.
- The presentation is part of a late-breaking poster presentation at EASL 2026 (May 27-30, 2026).
MetaVia Inc. announced that three late-breaking abstracts for its cardiometabolic drug candidates, DA-1726 and vanoglipel (DA-1241), have been accepted for poster presentations at the American Diabetes Association’s (ADA) 2026 Scientific Sessions.
📋 Key Facts
- The ADA 2026 Scientific Sessions will be held June 5-8, 2026, in New Orleans.
- DA-1726 is a novel dual oxyntomodulin (OXM) analog targeting GLP-1 and glucagon receptors for obesity treatment.
- Vanoglipel (DA-1241) is a novel G-protein-coupled receptor 119 (GPR119) agonist.
- Three late-breaking abstracts were accepted for presentation.
- The information was furnished under Item 7.01 and is not deemed 'filed' for regulatory purposes.
MetaVia Inc. announced its financial results for the first quarter ended March 31, 2026, and provided a corporate update. The filing includes a press release and an updated corporate presentation intended for investor communications.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026.
- Updated corporate presentation released on May 14, 2026.
- Press release furnished as Exhibit 99.1.
- Corporate presentation furnished as Exhibit 99.2.
MetaVia Inc. announced that a late-breaking abstract for its obesity drug candidate, DA-1726, has been accepted for a poster presentation at the EASL Congress 2026. The presentation will highlight the dual oxyntomodulin analog's mechanism targeting GLP-1 and glucagon receptors.
📋 Key Facts
- Late-breaking abstract for DA-1726 accepted for poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026.
- DA-1726 is a novel dual oxyntomodulin (OXM) analog targeting GLP-1 and glucagon receptors for obesity treatment.
- The EASL Congress 2026 is scheduled to take place May 27–30, 2026, in Barcelona, Spain.
- The disclosure was made under Item 7.01 (Regulation FD), which is typically furnished rather than filed.
MetaVia Inc. announced the dosing of the first patient in Part 3 of its Phase 1 clinical trial for DA-1726, a dual GLP-1 and glucagon receptor analog. This stage of the study will utilize 16-week titration cohorts to evaluate dose-escalation strategies and optimize patient tolerability.
📋 Key Facts
- First patient dosed in Part 3 of Phase 1 clinical trial for DA-1726 on April 10, 2026.
- DA-1726 is a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors.
- Part 3 consists of two 16-week titration cohorts designed to evaluate one-step and two-step dose-escalation strategies.
- The primary goal of this phase is to safely achieve higher target doses and optimize tolerability.
MetaVia Inc. filed a Form 8-K to furnish an updated corporate presentation for March 2026. The presentation is intended for use in upcoming investor communications and conferences.
📋 Key Facts
- The filing was made on March 26, 2026, under Item 7.01 (Regulation FD Disclosure).
- An updated corporate presentation was posted to the company's investor relations website.
- The presentation is included as Exhibit 99.1 to the filing.
- The information provided is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
MetaVia Inc. reported its financial results for the fiscal year ended December 31, 2025, and provided a corporate update. The announcement was made via a press release on March 26, 2026, and furnished under Item 2.02.
📋 Key Facts
- Announced financial results for the year ended December 31, 2025
- Provided a corporate update alongside financial results
- The report was filed under Item 2.02 (Results of Operations and Financial Condition)
- CEO Hyung Heon Kim signed the filing
MetaVia Inc. announced that it has received Institutional Review Board (IRB) approval to commence Phase 1 Part 3 of its clinical trial for DA-1726, a dual GLP-1 and glucagon receptor agonist. The trial will evaluate safety and efficacy in 40 obese subjects, with initial dosing expected in April 2026 and data results anticipated in Q4 2026.
📋 Key Facts
- IRB approval obtained from Clinical Pharmacology of Miami for Phase 1 Part 3 of DA-1726.
- DA-1726 is a novel, dual oxyntomodulin analog agonist targeting GLP-1 and glucagon receptors.
- The trial will enroll 40 obese, otherwise healthy adult subjects randomized 4:1 (active vs. placebo).
- Part 3A evaluates a one-step titration to 48 mg; Part 3B evaluates a two-step titration to 64 mg.
- Initial dosing is scheduled for April 2026.
- Top-line data readout is expected in the fourth quarter of 2026.
MetaVia Inc. filed this 8-K to disclose the determination of discretionary cash bonuses for its Named Executive Officers (CEO and CFO) for the fiscal year ended December 31, 2025.
📋 Key Facts
- The filing provides an updated Summary Compensation Table for 2025 and 2024 as required by Item 5.02(f).
- CEO Hyung Heon Kim received a $239,862 discretionary bonus in 2025, bringing total compensation to $756,328.
- CFO Marshall H. Woodworth received a $157,320 discretionary bonus in 2025, bringing total compensation to $562,985.
- The disclosure follows an earlier S-1 registration statement filed on January 5, 2026.
MetaVia Inc. completed a public offering of Class A and Class B units, raising approximately $7.7 million in net proceeds. The offering includes common stock and multiple series of warrants (Series C and D) to fund the clinical development of DA-1726 for obesity treatment.
🚩 Red Flags
- Significant dilution potential due to the issuance of nearly 3 million warrants (Series C and D) alongside common stock.
- The inclusion of 'Pre-Funded Warrants' in Class B units is a common mechanism used by micro-caps to avoid immediate large-scale ownership triggers, often signaling difficulty in raising straight equity.
📋 Key Facts
- Closed public offering on January 16, 2026.
- Net proceeds totaled approximately $7.7 million after discounts and expenses.
- Issued 1,006,870 Class A Units (including over-allotment) at $3.10 per unit.
- Issued 1,998,704 Class B Units at $3.099 per unit.
- Class A Units include one share of common stock and 1.5 Series C and 1.5 Series D warrants.
- Series D Warrants are callable by the company following positive Phase 1b Part III clinical trial data for DA-1726, provided stock exceeds $4.65 for 20 consecutive days.
- Underwriter: Ladenburg Thalmann & Co. Inc.
MetaVia Inc. announced preliminary unaudited financial results for the fiscal year ended December 31, 2025. The company reported a cash position of approximately $10.3 million with no outstanding debt.
🚩 Red Flags
- Information is preliminary and subject to significant uncertainty until the formal 10-K is filed.
📋 Key Facts
- Preliminary cash and cash equivalents balance: ~$10.3 million as of Dec 31, 2025.
- Reported zero ($0) outstanding debt as of Dec 31, 2025.
- Full financial results for FY2025 are expected to be released in March 2026.
- The reported figures are preliminary and unaudited.
MetaVia Inc. announced positive, statistically significant results from the eight-week multiple ascending dose (MAD) cohort of its Phase 1 clinical trial for DA-1726, a dual oxyntomodulin analog agonist intended for obesity treatment.
📋 Key Facts
- Clinical Trial: Phase 1, non-titrated 48 mg MAD cohort of DA-1726.
- Mechanism of Action: Dual oxyntomodulin (OXM) analog agonist acting on GLP1R and GCGR receptors.
- Results: Reported as 'positive' and 'statistically significant'.
- Trial Duration: Eight weeks (extended from the original four-week protocol).
- Indication: Treatment of obesity.
MetaVia Inc. has regained compliance with the Nasdaq Minimum Bid Price Requirement after its stock closed at $1.00 or greater for 10 consecutive business days. This resolves the previous non-compliance issue that had placed the company's listing at risk.
🚩 Red Flags
- Historical delisting risk due to low stock price (sub-$1.00).
📋 Key Facts
- The Company was previously in violation of Nasdaq Listing Rule 5550(a)(2) due to a closing bid price below $1.00 for 30 consecutive trading days.
- Nasdaq had granted the Company a 180-day extension on November 26, 2025, which was set to expire on May 26, 2026.
- The Company regained compliance via the closing bid price being at $1.00 or greater for the 10 consecutive business days from December 5, 2025, through December 18, 2025.
- Nasdaq notified the Company on December 19, 2025, that the matter is closed and the company is in compliance.
MetaVia Inc. (MTVA) is executing a 1-for-11 reverse stock split effective December 4, 2025. The action is intended to bring the company into compliance with Nasdaq's minimum bid price requirements.
🚩 Red Flags
- Reverse stock split (Red flag escalator)
- Nasdaq compliance risk (Delisting threat implied by the need for the split)
📋 Key Facts
- Reverse split ratio: 1-for-11
- Effective Date: December 4, 2025, at 5:00 p.m. ET
- Purpose: To comply with Nasdaq continued listing requirements
- Share count impact: Outstanding shares expected to decrease from ~25.4 million to ~2.3 million
- New CUSIP number: 64132R 503
- Fractional shares will be paid out in cash based on the last trading day's closing price
MetaVia Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, extending their deadline to May 26, 2026. The company is considering a reverse stock split (previously approved by stockholders) as a primary method to cure the deficiency.
🚩 Red Flags
- Delisting notice/non-compliance with Nasdaq minimum bid price rule.
- Potential for a reverse stock split (1-for-5 to 1-for-30) which is often viewed negatively by the market.
- History of failing to meet listing standards over multiple periods.
📋 Key Facts
- Nasdaq granted a 180-day extension to regain compliance with the Minimum Bid Price Requirement until May 26, 2026.
- The company failed to meet the $1.00 minimum bid price requirement for 30 consecutive trading days prior to May 29, 2025.
- Stockholders previously approved a reverse stock split ratio between 1-for-5 and 1-for-30 on June 30, 2025.
- The company reported over $5 million in stockholders' equity as of September 30, 2025.
MetaVia Inc. announced positive Phase 2a clinical trial data for its drug candidate vanoglipel (DA-1241) in treating metabolic dysfunction-associated steatohepatitis (MASH). The data shows significant improvements in glycemic control, liver health markers, and lipid profiles over a 16-week period.
📋 Key Facts
- Phase 2a trial evaluated vanoglipel (DA-1241), a GPR119 agonist, for MASH treatment.
- HbA1c reduction of -0.54%p with monotherapy and -0.66%p with combination therapy at Week 16.
- Significant reductions in plasma ALT levels observed in subjects with baseline ALT between 40-200 U/L.
- Improvements noted in liver steatosis (CAP) and liver stiffness (VCTE).
- Reduction in biomarkers for cell death (CK18F/M30), inflammation (hs-CRP, CCL2), and fibrosis (TIMP1).
- The drug was well tolerated with no treatment-emergent adverse events leading to discontinuation.
MetaVia Inc. has filed an 8-K to announce the posting of an updated corporate presentation on its investor relations website.
📋 Key Facts
- The company updated its corporate presentation on November 6, 2025.
- The presentation is intended for use in investor communications and conferences.
- The filing includes a forward-looking statements disclaimer regarding the contents of Exhibit 99.1.
MetaVia Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2025 and provided a corporate update via press release.
📋 Key Facts
- Report date: November 6, 2025
- Reporting period: Third Quarter ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and a corporate update.
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
MetaVia Inc. filed an 8-K to announce the posting of an updated corporate presentation on its investor relations website.
📋 Key Facts
- The company updated its corporate presentation on August 7, 2025.
- The presentation is intended for use in investor communications and conferences.
- The filing includes Exhibit 99.1 containing the new presentation.
MetaVia Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2025 and provided a corporate update via press release.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2025
- Filing date: August 7, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and a corporate update.
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
MetaVia Inc. issued a press release regarding an update to its Phase 1 clinical trial for DA-1726, a dual oxyntomodulin (OXM) analog agonist for obesity treatment. The company has extended the multiple ascending dose (MAD) cohort by four weeks and successfully administered the fifth weekly dose to the first patient.
🚩 Red Flags
- Clinical trial extensions can sometimes indicate slower-than-expected enrollment or safety monitoring requirements, though not explicitly stated here.
📋 Key Facts
- Clinical trial update: Phase 1 MAD cohort of DA-1726 has been extended from 4 weeks to 8 weeks.
- First patient in the MAD cohort has received their fifth weekly dose.
- DA-1726 is a dual GLP1R and GCGR agonist targeting obesity treatment.
MetaVia Inc. has entered into a research collaboration with Syntekabio, Inc., an AI-driven drug discovery company. The partnership aims to identify new disease targets and optimize the therapeutic profile of MetaVia's oral GPR119 agonist, DA-1241.
📋 Key Facts
- Collaboration announced on August 4, 2025.
- Partner: Syntekabio, Inc. (AI-driven drug discovery company).
- Focus: Research and optimization of therapeutic profile for DA-1241.
- Target Molecule: Oral G-Protein-Coupled Receptor 119 (GPR119) agonist.
MetaVia Inc. announced the dosing of the first patient in the 48 mg multiple ascending dose (MAD) cohort for its Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog agonist for obesity treatment. Top-line data from this study is anticipated in Q4 2025.
📋 Key Facts
- First patient dosed in the 48 mg multiple ascending dose (MAD) cohort of Phase 1 trial for DA-1726.
- DA-1726 is a dual oxyntomodulin (OXM) analog agonist targeting GLP1R and GCGR receptors.
- The drug is being developed for the treatment of obesity.
- Top-line clinical data is expected to be released in the fourth quarter of 2025.
MetaVia Inc. held its annual meeting of stockholders on June 30, 2025, where shareholders approved several critical measures including a reverse stock split and the issuance of additional shares to a private placement investor.
🚩 Red Flags
- Approval of a reverse stock split (often used to combat delisting or improve share price)
- Significant dilution risk via the approval of the Issuance Proposal related to pre-funded warrants from Dong-A Socio Holdings Co., Ltd.
- The combination of a reverse split and significant warrant exercises suggests potential liquidity or capital structure distress.
📋 Key Facts
- Stockholders approved a reverse stock split in a range of 1-for-5 to 1-for-30.
- Stockholders approved the issuance of common stock equal to or in excess of 20% of outstanding shares to satisfy pre-funded warrants held by Dong-A Socio Holdings Co., Ltd.
- Two Class III directors (Mark A. Glickman and Michael Salsbury) were elected to three-year terms ending in 2028.
- BDO USA, P.C. was ratified as the independent registered public accounting firm for fiscal year 2025.
- The company held a quorum of 15,364,255 shares present at the meeting.
MetaVia Inc. received a notice from Nasdaq informing the company it is in violation of the minimum bid price requirement after its stock closed below $1.00 for 30 consecutive business days. The company has until November 25, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq
- Stock price has been below $1.00 for 30 consecutive business days
- Potential requirement for a reverse stock split to maintain listing
📋 Key Facts
- Received Nasdaq notice on May 29, 2025.
- Violation of Nasdaq Marketplace Rule 5550(a)(2) (Minimum Bid Price Requirement).
- Compliance period expires November 25, 2025.
- To regain compliance, the stock must close at or above $1.00 for at least 10 consecutive business days.
- The company may need to effect a reverse stock split to qualify for an additional 180-day extension.
MetaVia Inc. filed an 8-K to announce the posting of an updated corporate presentation on its investor relations website.
📋 Key Facts
- Company posted an updated corporate presentation to https://ir.metaviatx.com/events-presentations/presentations on May 21, 2025.
- The presentation is intended for use in investor communications and conferences.
- Exhibit 99.1 contains forward-looking statements regarding the company's future performance.
MetaVia Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025 and provided a corporate update via press release.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2025
- Filing date: May 14, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and a corporate update.
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
MetaVia Inc. completed a $10 million private placement of common stock and pre-funded warrants to institutional investors on May 8, 2025. The proceeds are intended for working capital and the clinical development of their obesity treatment, DA-1726.
🚩 Red Flags
- Significant dilution: The issuance of over 9.4 million new shares at $0.71 represents a substantial increase in share count.
- Pre-funded warrants: These act as quasi-equity and can lead to immediate non-consensual dilution upon exercise (subject to stockholder approval).
- High cost of capital: The 9% placement agent fee is relatively high for a standard equity raise.
📋 Key Facts
- Gross proceeds from the private placement: approximately $10.0 million.
- Securities issued: 9,479,345 shares of common stock at $0.71 per share and 4,605,162 pre-funded warrants at $0.709 per warrant.
- Pre-funded warrants have an exercise price of $0.001 per share.
- Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent with a 9.0% cash fee plus up to $155,000 in expenses.
- The offering includes registration rights for the shares and warrant shares within 30-60 days of stockholder approval.
MetaVia Inc. announced the presentation of positive Phase 2a clinical trial data for its drug candidate DA-1241 at a major medical congress. The data suggests efficacy in treating metabolic dysfunction-associated steatohepatitis through hepatoprotective and glucose-regulating effects.
📋 Key Facts
- Presented Phase 2a clinical trial data for DA-1241 (G-Protein-Coupled Receptor 119 agonist) on May 7, 2025.
- Trial focused on patients with presumed metabolic dysfunction-associated steatohepatitis.
- Data demonstrated both hepatoprotective and glucose-regulating effects.
- Presentation occurred at the European Association for the Study of the Liver Congress 2025 in Amsterdam.
MetaVia Inc. issued a press release regarding positive top-line results from the Phase 1 clinical trial of its obesity drug candidate, DA-1726. The company also updated its corporate presentation to reflect current developments.
📋 Key Facts
- Reported top-line results from multiple ascending dose Part 2 of Phase 1 clinical trial for DA-1726.
- DA-1726 is a dual oxyntomodulin analog agonist (GLP-1 and glucagon receptor agonist).
- The company claims the drug demonstrates potential as a 'best-in-class' obesity treatment.
- Updated corporate presentation was released on April 22, 2025.
MetaVia Inc. announced the exercise of 1,430,000 pre-funded common stock purchase warrants and updated its corporate presentation.
🚩 Red Flags
- Dilution: The exercise of warrants resulted in the issuance of 1.43 million new shares, increasing the total share count to over 10 million.
📋 Key Facts
- On April 15, 2025, 1,430,000 Pre-Funded Common Stock Purchase Warrants were exercised.
- Following the exercise, total shares of common stock issued and outstanding increased to 10,084,869.
- No Pre-Funded Warrants remain outstanding as of April 15, 2025.
- The company updated its corporate presentation (Exhibit 99.1).
MetaVia Inc. announced positive Phase 1 clinical trial results for its obesity drug candidate, DA-1726, and updated its corporate presentation.
📋 Key Facts
- Announced positive results from the multiple ascending dose Part 2 of Phase 1 clinical trial for DA-1726.
- DA-1726 is a dual oxyntomodulin analog agonist (GLP-1 and glucagon receptor agonist) for obesity treatment.
- The company updated its corporate presentation on April 15, 2025.
MetaVia Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024, and provided a general corporate update via press release.
📋 Key Facts
- Report date: March 20, 2025
- Reporting period covered: Fiscal year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and corporate updates.
MetaVia Inc. filed an 8-K to disclose the posting of an updated corporate presentation on its website pursuant to Regulation FD.
📋 Key Facts
- The company updated its corporate presentation as of January 10, 2025.
- The presentation is available at https://www.metaviatx.com/events-presentations/presentations.
- The filing includes Exhibit 99.1 containing the presentation and forward-looking statements.
MetaVia Inc. issued a press release announcing positive top-line 16-week results from its Phase 2a clinical trial for treating metabolic dysfunction-associated steatohepatitis (MASH). The disclosure was made pursuant to Regulation FD.
📋 Key Facts
- Announced positive top-line 16-week results from a two-part Phase 2a clinical trial.
- The clinical trial targeted patients with presumed metabolic dysfunction-associated steatohepatitis (MASH).
- Disclosure made via press release attached as Exhibit 99.1.
MetaVia Inc. has filed an 8-K to disclose the posting of an updated corporate presentation on its website as part of a Regulation FD disclosure.
📋 Key Facts
- The company posted an updated corporate presentation on November 29, 2024.
- The presentation is available at https://www.metaviatx.com/events-presentations/presentations
- The filing includes Exhibit 99.1 containing the corporate presentation.
NeuroBo Pharmaceuticals, Inc. is undergoing a corporate rebranding, including a name change to MetaVia Inc. and a ticker symbol change from 'NRBO' to 'MTVA'. These changes are expected to be effective on November 29, 2024.
📋 Key Facts
- Company name changing from NeuroBo Pharmaceuticals, Inc. to MetaVia Inc., effective Nov 29, 2024.
- Ticker symbol changing from 'NRBO' to 'MTVA' on the Nasdaq Capital Market, expected effective Nov 29, 2024.
- The name change was achieved via a Certificate of Amendment filed with the Secretary of State of Delaware without a shareholder vote.
- Bylaws were amended and restated (Fourth Amended and Restated Bylaws) to reflect the name change.
- New corporate website metaviatx.com will launch on Nov 29, 2024.
NeuroBo Pharmaceuticals, Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2024 and provided a corporate update via press release.
📋 Key Facts
- Report date: November 7, 2024
- Reporting Period: Third Quarter ended September 30, 2024
- The filing includes an announcement of financial results and a corporate update (Exhibit 99.1).
- Ticker symbol listed as NRBO on Nasdaq.
NeuroBo Pharmaceuticals announced the completion of the last patient last visit (LPLV) for its Phase 2a clinical trial of DA-1241. The study evaluates the efficacy and safety of this GPR119 agonist for treating metabolic dysfunction-associated steatohepatitis (MASH).
📋 Key Facts
- Completed 'last patient last visit' in a two-part, Phase 2a clinical trial.
- Drug candidate: DA-1241 (GPR119 agonist).
- Target indication: Metabolic dysfunction-associated steatohepatitis (MASH).
- Announcement date: November 4, 2024.
NeuroBo Pharmaceuticals, Inc. filed an 8-K to announce the posting of an updated corporate presentation on its website as part of a Regulation FD disclosure.
📋 Key Facts
- The company updated its corporate presentation on October 7, 2024.
- The presentation is available via the company's website under the events/presentations section.
- The filing includes Exhibit 99.1 containing the corporate presentation.
NeuroBo Pharmaceuticals announced positive top-line safety, tolerability, and dose-linear pharmacokinetics (PK) data from the Single Ascending Dose (SAD) Part 1 of its Phase 1 clinical trial for DA-1726. The drug is a dual oxyntomodulin (OXM) analog agonist targeting obesity via GLP1R and GCGR receptors.
📋 Key Facts
- Announced positive top-line safety and tolerability data for DA-1726.
- Phase 1 clinical trial: Single Ascending Dose (SAD) Part 1 completed.
- DA-1726 is a dual oxyntomodulin (OXM) analog agonist (GLP1R and GCGR).
- Data indicates dose-linear pharmacokinetics (PK) for the candidate drug.
NeuroBo Pharmaceuticals, Inc. held a special meeting of stockholders on September 18, 2024, where shareholders approved the issuance of common stock exceeding 20% of outstanding shares to satisfy various warrants.
🚩 Red Flags
- Approval of issuance exceeding 20% of outstanding shares typically indicates significant dilution for existing shareholders.
📋 Key Facts
- Special Meeting held on September 18, 2024.
- Stockholders approved Proposal 1: Issuance of Common Stock in an amount equal to or in excess of 20% of the Common Stock outstanding (pursuant to Nasdaq Listing Rule 5635(d)).
- The issuance covers shares issuable upon exercise of Series A Warrants, Series B Warrants, and Placement Agent Warrants.
- Series A warrants relate to agreements dated June 23, 2024; Series B relates to previous private placements; Placement Agent warrants relate to an engagement letter with H.C. Wainwright & Co., LLC dated May 23, 2024.
- Proposal 1 received 2,987,855 votes in favor and 54,375 against.
NeuroBo Pharmaceuticals, Inc. issued an 8-K to announce its second quarter financial results for the period ended June 30, 2024, and provided a corporate strategic update.
📋 Key Facts
- Report date: August 14, 2024
- Reporting period: Second Quarter ended June 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and a strategic update.
- Ticker symbol listed in text as NRBO (Note: User prompt provided MTVA)
NeuroBo Pharmaceuticals announced the completion of participant enrollment for Part 1 of its Phase 1 clinical trial for DA-1726, a dual agonist targeting obesity. The trial involves 45 participants randomized into five cohorts to test the novel drug against a placebo.
📋 Key Facts
- Completed enrollment of Single Ascending Dose (SAD) Part 1 of Phase 1 clinical trial for DA-1726.
- DA-1726 is a dual oxyntomodulin (OXM) analog agonist acting on GLP1R and GCGR receptors.
- Total of 45 participants enrolled and randomized into 5 cohorts.
- Randomization ratio is 6:3 (drug to placebo) within each cohort.
NeuroBo Pharmaceuticals, Inc. has entered into a joint research agreement with Dong-A ST Co. Ltd. and ImmunoForge to develop a long-acting formulation of DA-1726 using ELP platform technology.
📋 Key Facts
- Signed a joint research agreement on August 6, 2024.
- Partnership includes Dong-A ST Co. Ltd. and ImmunoForge.
- Objective: Develop a long-acting, once-monthly formulation of DA-1726 (dual OXM analog agonist).
- Technology to be used: ImmunoForge’s Elastin-Like Polypeptide (ELP) platform technology for half-life extension.
NeuroBo Pharmaceuticals, Inc. has entered into an exclusive license agreement with MThera Pharma Co., Ltd. for the rights to NB-01, targeting the treatment of painful diabetic neuropathy.
📋 Key Facts
- The agreement is an exclusive license for NB-01.
- MThera Pharma Co., Ltd. (MTHERA) granted rights include conducting research and clinical trials.
- Potential Phase 3 clinical trials are planned for the United States and South Korea.
- Agreement covers future commercialization of NB-01.
NeuroBo Pharmaceuticals, Inc. filed an 8-K to provide notice of an updated corporate presentation posted on its website. This is a routine disclosure under Regulation FD.
📋 Key Facts
- The company updated its corporate presentation as of July 2024.
- The filing was made pursuant to Item 7.01 (Regulation FD Disclosure).
- The presentation contains forward-looking statements subject to standard legal limitations.
NeuroBo Pharmaceuticals announced the closing of a private placement and registered direct offering on June 25, 2024. Additionally, the company reported clinical progress regarding its Phase 1 trial for DA-1726, an obesity treatment.
🚩 Red Flags
- The closing of a registered direct offering often implies potential dilution for existing shareholders, though specific terms/price were not detailed in the 8-K text itself.
📋 Key Facts
- Closed a previously announced private placement and registered direct offering on June 25, 2024.
- Dosed the first patient in the Multiple Ascending Dose (MAD) Part 2 of its Phase 1 clinical trial for DA-1726.
- DA-1726 is a dual oxyntomodulin (OXM) analog agonist targeting GLP1R and GCGR receptors for obesity treatment.
NeuroBo Pharmaceuticals announced a combined registered direct offering and private placement (PIPE) totaling approximately $20 million in gross proceeds. The financing includes significant issuance of warrants to investors and the placement agent, potentially leading to substantial future dilution.
🚩 Red Flags
- Significant potential dilution due to massive issuance of Series A and B warrants tied to clinical milestones.
- Related-party transaction involving Dong-A ST Co. Ltd. in the PIPE portion.
- High cost of capital: Placement agent receives both cash fees and equity warrants.
📋 Key Facts
- Registered Direct Offering: 763,359 shares at $3.93 per share (approx. $3M gross).
- Private Placement (PIPE): Approximately $17 million in gross proceeds via sale of common stock/pre-funded warrants and various series of warrants.
- Total expected gross proceeds: ~$20 million.
- Related Party Involvement: Dong-A ST Co. Ltd. participated as a PIPE Purchaser.
- Warrant Issuance: Includes Series A Warrants (5,089,060 shares) and Series B Warrants (up to 7,633,591 shares) tied to clinical data readouts for DA-1726.
- Placement Agent Compensation: H.C. Wainwright & Co., LLC to receive 7.0% cash fee plus warrants representing 5% of the offering equity.
NeuroBo Pharmaceuticals announced positive pre-clinical data for its dual agonist DA-1726, which showed superiority in weight loss and lean body mass retention compared to survodutide in animal models. The findings were presented at the American Diabetes Association (ADA) 84th Scientific Sessions.
📋 Key Facts
- Pre-clinical data for DA-1726 demonstrated superiority in weight loss, retention of lean body mass, and lipid-lowering effects compared to survodutide.
- DA-1726 is a dual oxyntomodulin (OXM) analog agonist functioning as a GLP1R and GCGR agonist.
- Data was presented by Tae-Hyoung Kim at the ADA 84th Scientific Sessions in Orlando, Florida on June 22, 2024.
NeuroBo Pharmaceuticals, Inc. reported the results of its annual meeting held on June 7, 2024. Key outcomes included the election of three Class II directors and the approval of an amendment to the company's 2022 Equity Incentive Plan.
🚩 Red Flags
- Significant potential dilution through the automatic annual increase in equity incentive plan shares (10% per year for 8 years).
📋 Key Facts
- Stockholders approved a First Amendment to the 2022 Equity Incentive Plan on June 7, 2024.
- The amendment includes an automatic annual increase in shares available for awards of 10% of fully diluted shares from 2025 through 2032.
- The aggregate maximum number of shares for Incentive Stock Options is increased to 15,000,000 shares plus any annual increases.
- Three Class II directors (Jason L. Groves, Hyung Heon Kim, and Andrew Koven) were elected to three-year terms ending in 2027.
- BDO USA, P.C. was ratified as the independent registered public accounting firm for fiscal year 2024.
- The annual meeting saw a quorum of 3,704,835 shares, representing 75.5% of outstanding common stock.
NeuroBo Pharmaceuticals announced positive pre-clinical data for its candidate DA-1241, showing additive hepatoprotective effects when combined with semaglutide in MASH models. The company plans to present this data at the EASL Congress 2024.
📋 Key Facts
- Pre-clinical data suggests DA-1241 (GPR119 agonist) + semaglutide improves liver fibrosis in MASH models.
- The combination demonstrated additive hepatoprotective effects compared to monotherapy.
- Data will be presented via two poster presentations at the EASL Congress 2024 (June 5-8, 2024).
- Research conducted with Dong-A ST Research Center and Gubra.
NeuroBo Pharmaceuticals, Inc. issued an 8-K to announce its financial results for the first quarter ended March 31, 2024, and provided a corporate strategic update via press release.
📋 Key Facts
- Reporting period: First quarter ended March 31, 2024.
- Filing date: May 9, 2024.
- The filing includes results of operations and financial condition (Item 2.02).
- Includes a corporate strategic update via Exhibit 99.1.
NeuroBo Pharmaceuticals announced that its cardiometabolic assets, DA-1241 and DA-1726, have been accepted for poster presentations at two major medical congresses in June 2024.
📋 Key Facts
- Poster presentations accepted for assets DA-1241 and DA-1726.
- Presentations scheduled for EASL Congress 2024 (June).
- Presentations scheduled for ADA 84th Scientific Sessions (June).
NeuroBo Pharmaceuticals, Inc. announced the successful dosing of the first patient in its Phase 1 clinical trial for DA-1726, a dual agonist targeting obesity.
📋 Key Facts
- Dosed the first patient in the single ascending dose (SAD) Part 1 of a two-part Phase 1 clinical trial.
- The drug candidate is DA-1726, a novel dual oxyntomodulin (OXM) analog agonist.
- Mechanism of action involves glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR).
- Target indication is the treatment of obesity.
NeuroBo Pharmaceuticals, Inc. has released an updated corporate presentation via its website to provide investors with current information regarding the company's operations and outlook.
📋 Key Facts
- The company posted an updated corporate presentation on April 16, 2024.
- The presentation is available at https://www.neurobopharma.com/events-presentations/presentations.
- Information was furnished pursuant to Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
NeuroBo Pharmaceuticals announced the completion of patient enrollment for Part 1 of its Phase 2a clinical trial for DA-1241, targeting metabolic dysfunction-associated steatohepatitis (MASH). The trial is evaluating efficacy and safety across three treatment arms: 50 mg, 100 mg, and placebo.
📋 Key Facts
- Completed enrollment of Part 1 of a two-part Phase 2a clinical trial for DA-1241.
- DA-1241 is a G-Protein-Coupled Receptor 119 (GPR119) agonist.
- Target indication: metabolic dysfunction-associated steatohepatitis (MASH).
- Approximately 49 patients randomized in Part 1.
- Randomization ratio of 1:2:1 into DA-1241 50 mg, DA-1241 100 mg, or placebo.
NeuroBo Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023.
📋 Key Facts
- The filing is a standard announcement of annual financial results (Item 2.02).
- Results pertain to the fiscal year ending December 31, 2023.
- Press release containing detailed results was issued on March 28, 2024.
NeuroBo Pharmaceuticals announced that its Safety Review Committee (SRC) has recommended the continuation of its Phase 2a clinical trial for DA-1241 without modification. The drug is being tested as a GPR119 agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
📋 Key Facts
- Safety Review Committee (SRC) approved continuation of Phase 2a trial for DA-1241.
- The review was based on a blinded safety assessment of the first six months of study conduct.
- DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist.
- Target indication: Metabolic dysfunction-associated steatohepatitis (MASH).
- Full data readout from the Phase 2a trial is anticipated in the second half of 2024.
NeuroBo Pharmaceuticals, Inc. announced the appointment of Marshall H. Woodworth as Chief Financial Officer (CFO), Principal Financial Officer, and Principal Accounting Officer, effective March 1, 2024. This follows a period where Mr. Woodworth served as Acting CFO via an engagement agreement with WhiteCap Search Holdings, LLC.
🚩 Red Flags
- Transition from an 'Acting CFO' via a third-party service provider (WhiteCap Search Holdings) to a permanent executive is often seen in micro-caps facing rapid scaling or recent financial instability, though not inherently negative here.
📋 Key Facts
- Marshall H. Woodworth appointed as CFO, Principal Financial Officer, and Principal Accounting Officer effective March 1, 2024.
- The appointment involves the termination of a previous engagement agreement with WhiteCap Search Holdings, LLC.
- Mr. Woodworth's annual base salary is set at $380,000 with an annual incentive target of 40% of base salary.
- Grant of 33,496 Restricted Stock Units (RSUs) under the 2022 Equity Incentive Plan, vesting over a three-year period.
- The employment agreement includes standard severance and change in control provisions.
NeuroBo Pharmaceuticals announced the first IRB approval for a clinical site to begin Phase 1 trials of its obesity drug candidate, DA-1726. The company anticipates randomizing the first patient in Q2 2024.
📋 Key Facts
- Received first site Institutional Review Board (IRB) approval at Clinical Pharmacology of Miami in Hialeah, FL.
- The trial is for DA-1726, a dual oxyntomodulin (OXM) analog agonist targeting GLP1R and GCGR receptors.
- Target indication: Obesity treatment.
- First patient randomization is expected in the second quarter of 2024.
NeuroBo Pharmaceuticals, Inc. has released an updated corporate presentation to its website as of February 14, 2024. The filing is intended to provide updated information regarding the company's business and activities via Exhibit 99.1.
📋 Key Facts
- Company posted an updated corporate presentation to its website on February 14, 2024.
- The presentation is provided as Exhibit 99.1.
- Information is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
NeuroBo Pharmaceuticals announced that the FDA has cleared its Investigational New Drug (IND) application for DA-1726, a dual oxyntomodulin analog agonist. The company intends to begin Phase 1 clinical trials for obesity treatment in H1 2024.
📋 Key Facts
- FDA clearance received for IND application of DA-1726.
- DA-1726 is a dual oxyntomodulin (OXM) analog agonist targeting GLP1R and GCGR receptors.
- Target indication: Obesity treatment.
- Phase 1 clinical trials are scheduled to initiate in the first half of 2024.
NeuroBo Pharmaceuticals announced positive pre-clinical safety data for its drug candidate DA-1241 in combination with sitagliptin. Additionally, the company has opened enrollment for Part 2 of its Phase 2a clinical trial for treating metabolic dysfunction-associated steatohepatitis (MASH) following FDA protocol approval.
📋 Key Facts
- Announced positive pre-clinical safety data for DA-1241 (GPR119 agonist) when combined with sitagliptin (DPP4 inhibitor).
- FDA has satisfied a 45-day commitment regarding an amended protocol.
- Enrollment is now open for Part 2 of the Phase 2a clinical trial for MASH treatment.
NeuroBo Pharmaceuticals, Inc. has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company is no longer under threat of delisting regarding this specific rule.
🚩 Red Flags
- Historical non-compliance with Nasdaq's $1.00 minimum bid price rule indicates previous extreme volatility or significant downward pressure on stock price.
📋 Key Facts
- Received formal notification from Nasdaq on January 8, 2024.
- Regained compliance with Nasdaq Listing Rule 5550(a)(2) (minimum $1.00 closing bid price).
- Nasdaq confirmed the company satisfies all other applicable criteria for continued listing.
- The delisting matter regarding the minimum bid requirement is now officially closed.